

CDC's ACIP meets to discuss COVID-19 vaccine boosters

- On April 20, 2022, the Center for Disease Control and Prevention's (CDC's) <u>Advisory Committee</u> for <u>Immunization Practices (ACIP) Committee met</u> to discuss COVID-19 vaccine policy and updates on the effectiveness and safety of booster doses.
- The <u>ACIP COVID-19 vaccine work group supports</u> the recent <u>CDC recommendation</u> that immunocompromised individuals ages 12 and over and people over the age of 50 may receive a second COVID-19 mRNA vaccine booster dose.
 - The CDC recommendations follow the <u>FDA's regulatory actions</u> authorizing second booster doses for these individuals.
- The second COVID-19 vaccine booster dose should be administered at least 4 months after the first booster dose.
- The current recommendation allows for flexibility, giving patients and providers access to the vaccine booster dose and the ability to decide based on individual factors and timing.
- Eligible people who may consider getting the second booster dose as soon as possible:
 - People with certain underlying medical conditions that increase the risk of severe COVID-19 illness
 - People who are moderately or severely immunocompromised
 - People who live with someone who is immunocompromised, at increased risk for severe disease, or who cannot be vaccinated due to age or contraindication
 - People at increased risk of exposure to SARS-CoV-2, such as through occupational, institutional, or other activities (eg, travel or large gatherings)
 - People living or working in an area where the COVID-19 community level is medium or high.
- As of April 19, 2022, approximately 1.1 million second COVID-19 vaccine booster doses have been given in adults ages 50 to 64 years and 3.2 million second booster doses have been given in adults ages ≥ 65 years since the authorization.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.